Antibody-Based Cancer Immunotherapy

EP. 1: Introduction: Immunotherapy Research Milestones

July 18th 2014

EP. 2: Checkpoint Inhibitors in Metastatic Melanoma

July 18th 2014

EP. 3: Future Role of Checkpoint Inhibitors in Melanoma

July 18th 2014

EP. 4: Checkpoint Inhibitor Combination Strategies

July 18th 2014

EP. 5: Adjuvant Ipilimumab in High-Risk Melanoma

July 18th 2014

EP. 6: PD-L1 Inhibition With MPDL3280A in Bladder Cancer

July 18th 2014

EP. 7: Future Role of Immunotherapy in Cancer

July 18th 2014

EP. 8: Targeted Immunotherapy in Cancer

July 18th 2014

EP. 9: PD-L1 Immunotherapy in Bladder Cancer

July 18th 2014

EP. 10: Evolving Role of PD-L1 as a Biomarker

July 18th 2014

EP. 11: Utility of PD-L1 as a Biomarker in Bladder Cancer

July 18th 2014

EP. 12: Checkpoint Inhibition in Renal Cell Carcinoma

July 18th 2014

EP. 13: Development of Checkpoint Inhibitors for GU Cancers

July 18th 2014

EP. 14: Rini Explores PD-1 Inhibition in Renal Cell Carcinoma

July 18th 2014

EP. 15: Evolving Renal Cell Carcinoma Treatment Paradigm

July 18th 2014

EP. 16: Immune Checkpoint Inhibitors in NSCLC

July 18th 2014

EP. 17: Optimizing Checkpoint Inhibition in NSCLC

July 18th 2014

EP. 18: Sequencing Checkpoint Inhibitors in NSCLC

July 18th 2014

EP. 19: Immunotherapy Combination Strategies in RCC

July 18th 2014

EP. 20: PD-1 Combinations Explored in RCC

July 18th 2014

NEXT PAGE
PREVIOUS PAGE